<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>My Biopharma News Feed</title><link>http://yourdomain-or-some-place.com/custom_feed.xml</link><description>Daily curated &amp; AI-summarized biopharma news.</description><atom:link href="http://yourdomain-or-some-place.com/custom_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Fri, 07 Mar 2025 02:32:03 +0000</lastBuildDate><item><title>Nonviral CRISPR-based knock-in of chimeric antigen receptor transgenes into T cells for cell therapy</title><link>https://www.fiercebiotech.com/premium/webinar/1368397</link><description>Discover how Cas9-CLIPT technology revolutionizes CAR T cell therapy by enabling precise, nonviral CRISPR-based knock-ins via homology-directed repair, boosting efficiency and accuracy in cell manufacturing. Join experts Krishanu Saha, PhD, and Max Sellman in this webinar to explore cutting-edge genome editing strategies and their transformative applications in cell therapy production.</description><pubDate>Fri, 14 Feb 2025 19:52:23 +0000</pubDate></item><item><title>Is Your CDMO Truly Commercial Ready?</title><link>https://www.fiercebiotech.com/resource/your-cdmo-truly-commercial-ready</link><description>Is your CDMO truly commercial-ready? Even if your drug isn't market-ready, selecting a partner prepared for large-scale manufacturing is critical—discover how to choose a CDMO that ensures long-term success and download the essential guide to get started.</description><pubDate>Tue, 18 Feb 2025 21:06:07 +0000</pubDate></item><item><title>Transforming Early Detection in Oncology and Rare Diseases Using AI</title><link>https://www.fiercebiotech.com/premium/webinar/1368565</link><description>AI is revolutionizing early detection in oncology and rare diseases by unlocking insights from unstructured healthcare data, addressing the global challenge of delivering better care with fewer resources while improving life expectancy and reducing costs. Join experts Chris Tackaberry and Dr. Will Ricketts in this webinar to explore real-world AI successes, including case studies and outcomes published in ASCO and Nature, demonstrating streamlined diagnosis and enhanced patient care strategies.</description><pubDate>Mon, 24 Feb 2025 14:53:21 +0000</pubDate></item><item><title>The Oncology Market: 2025 Outlook</title><link>https://www.fiercebiotech.com/resource/oncology-market-2025-outlook</link><description>2025 is poised to transform oncology with four key trends driving innovations in therapies and reshaping the market landscape, according to Blue Matter Consulting’s whitepaper. Discover how advancements in personalized medicine, next-gen treatments, and strategic industry shifts will redefine cancer care and create new opportunities in the life sciences sector.</description><pubDate>Tue, 25 Feb 2025 14:49:58 +0000</pubDate></item><item><title>Redefining vaccine trial recruitment</title><link>https://www.fiercebiotech.com/resource/redefining-vaccine-trial-recruitment</link><description>Clinical trials are essential for vaccine development but require innovative approaches to overcome recruitment challenges and ensure diverse participant cohorts. Avacare's new whitepaper offers data-driven strategies to revolutionize trial efficiency, diversity, and quality through targeted recruitment solutions.</description><pubDate>Wed, 26 Feb 2025 14:26:35 +0000</pubDate></item><item><title>Solutions for CAR-Engineered Cell Characterization</title><link>https://www.fiercebiotech.com/resource/solutions-car-engineered-cell-characterization</link><description>CST introduces purpose-built tools to accelerate CAR-engineered cell characterization, leveraging recombinant antibodies targeting scFv linkers like G4S and Whitlow/218 to streamline development. These solutions reduce reliance on costly anti-idiotype antibody development and simplify workflows, speeding time-to-results for CAR therapies.</description><pubDate>Wed, 26 Feb 2025 14:49:25 +0000</pubDate></item><item><title>Successful Scale-Up Of An Upstream Viral Vector Process Using An Adherent Platform</title><link>https://www.fiercebiotech.com/premium/webinar/1368645</link><description>Discover how scalable, adherent platforms can overcome viral vector manufacturing challenges to accelerate cell and gene therapies, as explored in a webinar detailing a successful helper-dependent adenovirus (HDAd) process from bench-scale optimization to commercial-scale production. Learn key strategies for achieving cost-effective scalability and tech transfer using single-use systems to meet urgent patient needs while managing bioprocessing complexities.</description><pubDate>Thu, 27 Feb 2025 16:40:10 +0000</pubDate></item><item><title>Accelerating and Enabling Consistency of Bioprocessing Scale-up</title><link>https://www.fiercebiotech.com/premium/webinar/1368685</link><description>This webinar explores cutting-edge strategies to streamline bioprocessing scale-up for monoclonal antibody production, focusing on media optimization, High-Intensity Perfusion systems, and advanced bioreactor designs to boost efficiency and sustainability. Experts Vivian Ott and Maren Grun will share actionable insights, case studies, and solutions for overcoming scaling challenges, from lab to commercial manufacturing.</description><pubDate>Fri, 28 Feb 2025 19:38:30 +0000</pubDate></item><item><title>3 Ways to Ensure Your Marketing Fills Your Life Science BD Pipeline</title><link>https://www.fiercebiotech.com/resource/3-ways-ensure-your-marketing-fills-your-life-science-bd-pipeline</link><description>Struggling to fill your life science business development pipeline with qualified leads? Scorr Marketing’s new e-book outlines three essential strategies—audience targeting, compelling storytelling, and performance tracking—to align marketing efforts with business development goals and keep your pipeline thriving.</description><pubDate>Tue, 04 Mar 2025 06:44:11 +0000</pubDate></item><item><title>Using Client Centricity as Fuel for Innovative Biologics Development and Manufacturing Solutions</title><link>https://www.fiercebiotech.com/resource/using-client-centricity-fuel-innovative-biologics-development-and-manufacturing-solutions</link><description>Rentschler Biopharma's new whitepaper offers actionable insights for biopharma professionals aiming to enhance biologics development and manufacturing through client-centric innovation without sacrificing quality. Tailored for process scientists, manufacturing leads, and executives, it serves as a guide to modern solutions that streamline production while maintaining high standards.</description><pubDate>Tue, 04 Mar 2025 16:39:29 +0000</pubDate></item><item><title>Trump administration policies could create headwinds across healthcare: Fitch</title><link>https://www.biopharmadive.com/news/trump-administration-policies-create-headwinds-healthcare-fitch-ratings/741615/</link><description>Fitch Ratings warns that the Biden administration's new initiatives, including drug pricing policies, could threaten the credit ratings of major pharmaceutical companies and other industries. The report highlights potential financial pressures from regulatory changes, signaling risks for corporations navigating evolving government reforms.</description><pubDate>Tue, 04 Mar 2025 21:00:00 +0000</pubDate></item><item><title>Bayer braces for ‘difficult’ year before turnaround pays dividends</title><link>https://www.biopharmadive.com/news/bayer-2024-results-restructuring-bill-anderson/741606/</link><description>CEO Bill Anderson alerted investors of potential profit declines in 2025 amid an ongoing corporate restructuring, signaling short-term challenges. The overhaul aims to reset the company’s path, with Anderson confident it will spark an "improved trajectory" starting in 2026.</description><pubDate>Wed, 05 Mar 2025 16:38:00 +0000</pubDate></item><item><title>Jazz expands in oncology with $935M deal for Chimerix</title><link>https://www.biopharmadive.com/news/jazz-chimerix-acquisition-cancer-drug-dordaviprone/741636/</link><description>Chimerix is poised for a potential regulatory breakthrough as it awaits the FDA's decision on accelerated approval for its experimental glioma treatment, a move that could address a critical unmet need in brain cancer care. The outcome, eagerly anticipated by investors and patients alike, hinges on whether the agency greenlights the drug based on promising early data despite pending confirmation of its full clinical benefits.</description><pubDate>Wed, 05 Mar 2025 16:53:00 +0000</pubDate></item><item><title>Tris to ask for approval of dual-acting pain drug</title><link>https://www.biopharmadive.com/news/tris-pain-drug-data-fda-approval-filing-plans/741727/</link><description>A company's experimental drug, which employs a novel mechanism distinct from current pain medications, shows promising results in two acute pain trials, boosting confidence in its potential market approval. The breakthrough could offer a fresh alternative for pain management amid ongoing efforts to address limitations of existing therapies.</description><pubDate>Thu, 06 Mar 2025 14:30:00 +0000</pubDate></item><item><title>Amgen readies pivotal MariTide trials; Novo offers discounted Wegovy</title><link>https://www.biopharmadive.com/news/amgen-maritide-trials-duchenne-base-editing-wegovy-discount/741651/</link><description>Amgen’s Phase 3 trials for its promising obesity drug were disclosed in a federal registry, advancing efforts to enter the competitive weight-loss market. Meanwhile, the FDA greenlit clinical testing of the first-ever base-editing therapy, aiming to treat Duchenne muscular dystrophy with precision gene-editing technology.</description><pubDate>Thu, 06 Mar 2025 15:06:00 +0000</pubDate></item><item><title>The top 3 impacts of Trump’s health data purge</title><link>https://www.biopharmadive.com/news/top-3-impacts-trump-health-data-purge/741744/</link><description>Disruptions in healthcare data access are worsening patient outcomes and may severely erode public trust in the U.S. medical system, experts warn. These breakdowns, already impacting care quality, could have lasting repercussions on the credibility of healthcare infrastructure if left unaddressed.</description><pubDate>Thu, 06 Mar 2025 15:38:00 +0000</pubDate></item><item><title>Federal judge extends block on Trump plan to limit NIH payouts</title><link>https://www.biopharmadive.com/news/biotech-nih-funding-indirect-costs-trump-preliminary-injunction/741733/</link><description>A federal judge has blocked the Biden administration's plan to limit indirect costs—such as overhead expenses for facilities and administration—that research institutions charge on NIH grants, delivering a win for the U.S. drug industry. The nationwide preliminary injunction halts a policy critics argued would stifle biomedical innovation by reducing funds that universities and labs rely on to support grant-backed projects.</description><pubDate>Thu, 06 Mar 2025 16:16:00 +0000</pubDate></item><item><title>Makary, under review to run FDA, evades pressure to reinstate canceled vaccine meeting</title><link>https://www.biopharmadive.com/news/makary-senate-hearing-fda-vaccines-meeting/741765/</link><description>Trump’s FDA pick vowed during a Senate hearing to reassess which critical scientific issues require input from independent advisory committees, signaling potential shifts in regulatory decision-making processes. The nominee faced scrutiny from lawmakers over how the agency might balance external expert review with internal evaluations under his leadership.</description><pubDate>Thu, 06 Mar 2025 17:30:00 +0000</pubDate></item><item><title>Following FDA cuts, Trump nominee Makary vows ‘independent’ staff review</title><link>https://www.biopharmadive.com/news/makary-hearing-fda-staffing-review-layoffs/741807/</link><description>A Johns Hopkins surgeon underscored the agency's significant growth, emphasizing a commitment to equipping key staff with "all the resources they need to do their job well." The pledge aims to ensure operational efficiency and support amid rapid expansion, aligning resources with the organization's evolving demands.</description><pubDate>Thu, 06 Mar 2025 20:42:00 +0000</pubDate></item><item><title>Vertex’s new pain drug gets first coverage nod from major insurer</title><link>https://www.biopharmadive.com/news/vertex-journavx-optum-united-health-coverage-tier-3/741850/</link><description>Optum, a UnitedHealth Group-owned pharmacy benefit manager, has temporarily added Journavx to certain commercial drug coverage lists as part of an interim decision pending a full review. The move allows coverage access while the company conducts a formal evaluation to finalize its formulary placement.</description><pubDate>Thu, 06 Mar 2025 22:59:00 +0000</pubDate></item></channel></rss>
